What were Panacea Biotec Ltd's latest quarterly results?
Panacea Biotec Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +49.7% (stable)
- Revenue Growth YoY: +25.8%
- Operating Margin: 1.5% (volatile)
Panacea Biotec Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +62.0%Weak
In , Panacea Biotec Ltd (Pharma - Others) is outperforming Nifty 500 with +62.0% relative strength. Fundamentals: Weak.
Panacea Biotec Ltd Key Facts
- Market Cap
- ₹3,413 Cr
- PAT Growth YoY
- +50%
- Revenue Growth YoY
- +26%
- OPM
- 1.5%
- RS vs Nifty 500
- +62.0%
Emerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
🌐FII stake increased 0.7% this quarter
💰Trading 56% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+50%
Stable
Revenue YoY
+26%
Stable
Operating Margin
1.5%
+2182 bps YoY
Current Price
₹557
Fundamental Score
31/100
Weak
3Y PAT CAGR
+22%
Market Cap
3.4K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Panacea Biotec Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +26% | +12% | Stable |
| PAT (Net Profit) | +50% | +22% | Stable |
| OPM | 1.5% | +2182 bps | Volatile |
Other Top Pharma - Others Stocks Beating Nifty 500
Frequently Asked Questions: Panacea Biotec Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Panacea Biotec Ltd's profit growing or declining?
Panacea Biotec Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +49.7% (latest quarter)
- PAT Growth QoQ: -125.7% (sequential)
- 3-Year PAT CAGR: +22.2%
- Trend: Stable — consistent growth pattern
What is Panacea Biotec Ltd's revenue growth trend?
Panacea Biotec Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +25.8%
- Revenue Growth QoQ: +0.9% (sequential)
- 3-Year Revenue CAGR: +11.6%
How is Panacea Biotec Ltd's operating margin trending?
Panacea Biotec Ltd's operating margin is volatile.
- Current OPM: 1.5%
- OPM Change YoY: +21.8% basis points
- OPM Change QoQ: -5.6% basis points
What is Panacea Biotec Ltd's 3-year profit and revenue CAGR?
Panacea Biotec Ltd's long-term compounding rates
- 3-Year Profit CAGR: +22.2%
- 3-Year Revenue CAGR: +11.6%
Is Panacea Biotec Ltd's growth accelerating or decelerating?
Panacea Biotec Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +62.1% bps
- Sequential Acceleration: -100.0% bps
What is Panacea Biotec Ltd's trailing twelve month (TTM) performance?
Panacea Biotec Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹-7 Cr
- TTM PAT Growth: +17.9% YoY
- TTM Revenue: ₹640 Cr
- TTM Revenue Growth: +14.4% YoY
- TTM Operating Margin: -0.7%
Is Panacea Biotec Ltd overvalued or undervalued?
Panacea Biotec Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Price-to-Book: 4.1x
What is Panacea Biotec Ltd's price-to-book ratio?
Panacea Biotec Ltd's price-to-book ratio is 4.1x.
- Price-to-Book (P/B): 4.1x
- Book Value per Share: ₹136
- Current Price: ₹557
Is Panacea Biotec Ltd a fundamentally strong company?
Panacea Biotec Ltd is rated Weak with a fundamental score of 31.12/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +25.8% (10% weight)
- PAT Growth YoY: +49.7% (10% weight)
- PAT Growth QoQ: -125.7% (10% weight)
- Margins stable (10% weight)
Is Panacea Biotec Ltd debt free?
Panacea Biotec Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹24 Cr
What is Panacea Biotec Ltd's return on equity (ROE) and ROCE?
Panacea Biotec Ltd's return ratios over recent years
- FY2024: ROCE -4.0%
- FY2025: ROCE -5.0%
- FY2026: ROCE -2.0%
Is Panacea Biotec Ltd's cash flow positive?
Panacea Biotec Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹17 Cr
- Free Cash Flow (FCF): ₹-23 Cr
What is Panacea Biotec Ltd's dividend yield?
Panacea Biotec Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹557
Who holds Panacea Biotec Ltd shares — promoters, FII, DII?
Panacea Biotec Ltd's shareholding pattern (Mar 2026)
- Promoters: 72.5%
- FII (Foreign): 1.6%
- DII (Domestic): 2.0%
- Public: 24.0%
Is promoter holding increasing or decreasing in Panacea Biotec Ltd?
Panacea Biotec Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 72.5% (Mar 2026)
- Previous Quarter: 72.5% (Dec 2025)
- Change: 0.00% (stable)
How long has Panacea Biotec Ltd been outperforming Nifty 500?
Panacea Biotec Ltd has been outperforming Nifty 500 for 3 consecutive weeks, indicating early-stage outperformance.
Is Panacea Biotec Ltd a new momentum entry or an established outperformer?
Panacea Biotec Ltd is an established outperformer with 3 weeks of consecutive Nifty 500 outperformance.
Is Panacea Biotec Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Panacea Biotec Ltd may be worth studying
- Earnings growing at +49.7% YoY
- Cash flow is positive — CFO ₹17 Cr
What is the investment thesis for Panacea Biotec Ltd?
Panacea Biotec Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +25.8% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Panacea Biotec Ltd?
Panacea Biotec Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.